Search

Your search keyword '"Atar, Daniel"' showing total 19 results
Start Over Author "Atar, Daniel"
19 results on '"Atar, Daniel"'

1. Immunocytokines with target cell–restricted IL-15 activity for treatment of B cell malignancies

Author

Zekri, Latifa, primary, Hagelstein, Ilona, additional, Märklin, Melanie, additional, Klimovich, Boris, additional, Christie, Mary, additional, Lindner, Cornelia, additional, Kämereit, Sofie, additional, Prakash, Nisha, additional, Müller, Stefanie, additional, Stotz, Sophie, additional, Maurer, Andreas, additional, Greve, Carsten, additional, Schmied, Bastian, additional, Atar, Daniel, additional, Rammensee, Hans-Georg, additional, Jung, Gundram, additional, and Salih, Helmut R., additional

Published
2024
Full Text
View/download PDF

2. Rational Combinatorial Targeting by Adapter CAR T Cells (AdCAR-T) Prevents Antigen Escape in Acute Myeloid Leukemia (AML)

Author

Atar, Daniel Bünyamin, primary, Ruoff, Lara, additional, Mast, Anna-Sophia, additional, Krost, Simon, additional, Moustafa-Oglou, Moustafa, additional, Scheuermann, Sophia, additional, Kristmann, Beate, additional, Feige, Maximilian, additional, Canak, Aysegül, additional, Wolsing, Katrin, additional, Schilbach, Karin, additional, Zekri, Latifa, additional, Ebinger, Martin, additional, Nixdorf, Daniel, additional, Subklewe, Marion, additional, Schulte, Johannes, additional, Lengerke, Claudia, additional, Werchau, Niels, additional, Mittelstaet, Joerg, additional, Lang, Peter, additional, Handgretinger, Rupert, additional, Schlegel, Patrick, additional, and Seitz, Christian Martin, additional

Published
2023
Full Text
View/download PDF

3. CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome

Author

Pecher, Ann-Christin, primary, Hensen, Luca, additional, Klein, Reinhild, additional, Schairer, Rebekka, additional, Lutz, Katrin, additional, Atar, Daniel, additional, Seitz, Christian, additional, Stanger, Anna, additional, Schneider, Janine, additional, Braun, Christiane, additional, Schmidt, Marina, additional, Horger, Marius, additional, Bornemann, Antje, additional, Faul, Christoph, additional, Bethge, Wolfgang, additional, Henes, Joerg, additional, and Lengerke, Claudia, additional

Published
2023
Full Text
View/download PDF

4. Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia

Author

Atar, Daniel, Ruoff, Lara, Mast, Anna-Sophia, Krost, Simon, Moustafa-Oglou, Moustafa, Scheuermann, Sophia, Kristmann, Beate, Feige, Maximilian, Canak, Aysegül, Wolsing, Kathrin, Schlager, Lennart, Schilbach, Karin, Zekri, Latifa, Ebinger, Martin, Nixdorf, Daniel, Subklewe, Marion, Schulte, Johannes, Lengerke, Claudia, Jeremias, Irmela, Werchau, Niels, Mittelstaet, Joerg, Lang, Peter, Handgretinger, Rupert, Schlegel, Patrick, and Seitz, Christian M.

Abstract

Targeting AML by chimeric antigen receptor T-cells (CAR-T) is challenging due to the promiscuous expression of AML-associated antigens in healthy hematopoiesis and high degree of inter- and intratumoral heterogeneity. Here, we present single-cell expression data of AML-associated antigens in 30 primary pediatric AML samples. We identified CD33, CD38, CD371, IL1RAP and CD123 as the most frequently expressed. Notably, high variability was observed not only across the different patient samples but also among leukemic cells of the same patient suggesting the necessity of multiplexed targeting approaches. To address this need, we utilized our modular Adapter CAR (AdCAR) platform, enabling precise qualitative and quantitative control over CAR-T-cell function. We show highly efficient and target-specific activity for newly generated adapter molecules (AMs) against CD33, CD38, CD123, CD135 and CD371, both in vitro and in vivo. We reveal that inherent intratumoral heterogeneity in antigen expression translates into antigen escape and therapy failure to monotargeted CAR-T therapy. Further, we demonstrate in PDX models that rational combinatorial targeting by AdCAR-T-cells can cure heterogenic disease. In conclusion, we elucidate the clinical relevance of heterogeneity in antigen expression in pediatric AML and present a novel concept for precision immunotherapy by combinatorial targeting utilizing the AdCAR platform.

Published
2024
Full Text
View/download PDF

5. Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation

Author

Heinz, Amadeus T, primary, Calkoen, Friso G.J., additional, Derbich, Alexander, additional, Miltner, Lea, additional, Seitz, Christian, additional, Doering, Michaela, additional, Braun, Christiane, additional, Atar, Daniel, additional, Schumm, Michael, additional, Heubach, Florian, additional, Arendt, Anne-Marie, additional, Schulz, Ansgar, additional, Schuster, Friedhelm R, additional, Meisel, Roland, additional, Strahm, Brigitte, additional, Finke, Juergen, additional, Heineking, Beatrice, additional, Stetter, Susanne, additional, Silling, Gerda, additional, Stachel, Daniel, additional, Gruhn, Bernd, additional, Debatin, Klaus-Michael, additional, Foell, Juergen, additional, Schulte, Johannes H, additional, Woessmann, Wilhelm, additional, Mauz-Körholz, Christine, additional, Tischer, Johanna, additional, Feuchtinger, Tobias, additional, Handgretinger, Rupert, additional, and Lang, Peter, additional

Published
2023
Full Text
View/download PDF

6. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL

Author

Ureña-Bailén, Guillermo, primary, Dobrowolski, Jérôme-Maurice, additional, Hou, Yujuan, additional, Dirlam, Alicia, additional, Roig-Merino, Alicia, additional, Schleicher, Sabine, additional, Atar, Daniel, additional, Seitz, Christian, additional, Feucht, Judith, additional, Antony, Justin S., additional, Mohammadian Gol, Tahereh, additional, Handgretinger, Rupert, additional, and Mezger, Markus, additional

Published
2022
Full Text
View/download PDF

8. Low Graft Invariant Natural Killer T-Cell Dose Is a Risk Factor for Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell Transplantation

Author

Schneidawind, Dominik, primary, Duerr-Stoerzer, Silke, additional, Liewer, Sonja, additional, Renner, Susanne, additional, Sánchez Navarro, Beatriz, additional, Atar, Daniel, additional, Keppeler, Hildegard, additional, Beck, Robert, additional, Hamprecht, Klaus, additional, Kanz, Lothar, additional, Lengerke, Claudia, additional, and Schneidawind, Corina, additional

Published
2022
Full Text
View/download PDF

9. IMMU-11. Evaluation of CAR-T cells targeting CD276 in medulloblastoma

Author

da Silva, Patricia Benites Goncalves, primary, Sieber, Laura, additional, Mack, Norman, additional, Atar, Daniel, additional, Kutscher, Lena M, additional, Schlegel, Patrick, additional, Ebinger, Martin, additional, Kawauchi, Daisuke, additional, Seitz, Christian, additional, and Pfister, Stefan M, additional

Published
2022
Full Text
View/download PDF

10. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment

Author

Seitz, Christian Martin, Flaadt, Tim, Mezger, Markus, Lang, Anne-Marie, Michaelis, Sebastian, Katz, Marie, Syring, Desireé, Joechner, Alexander, Rabsteyn, Armin, Siebert, Nikolai, Troschke-Meurer, Sascha, Zumpe, Maxi, Lode, Holger N., Yang, Sile F., Atar, Daniel, Mast, Anna-Sophia, Scheuermann, Sophia, Heubach, Florian, Handgretinger, Rupert, Lang, Peter, and Schlegel, Patrick

Subjects
haploidentical allogeneic stem cell transplantation, Time Factors, Immunology, Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, GD2 antibody therapy, Neuroblastoma, Antineoplastic Agents, Immunological, Treatment Outcome, immunomonitoring immunotherapy, Monitoring, Immunologic, Predictive Value of Tests, Gangliosides, Transplantation, Haploidentical, Cytokines, Feasibility Studies, Humans, Prospective Studies, Inflammation Mediators, Neoplasm Recurrence, Local, complement-dependent cytotoxicity, Original Research, antibody-dependent cellular cytotoxicity, Neoplasm Staging
Abstract

Haploidentical stem cell transplantation (haplo SCT) in Stage IV neuroblastoma relapsed patients has been proven efficacious, while immunotherapy utilizing the anti-GD2 antibody dinutuximab beta has become a standard treatment for neuroblastoma. The combinatorial therapy of haplo SCT and dinutuximab may potentiate the efficacy of the immunotherapy. To gain further understanding of the synergistic effects, functional immunomonitoring was assessed during the clinical trial CH14.18 1021 Antibody and IL2 After haplo SCT in Children with Relapsed Neuroblastoma (NCT02258815). Rapid immune reconstitution of the lymphoid compartment was confirmed, with clinically relevant dinutuximab serum levels found in all patients over the course of treatment. Only one patient developed human anti-chimeric antibodies (HACAs). In-patient monitoring revealed highly functional NK cell posttransplant capable of antibody-dependent cellular cytotoxicity (ADCC). Degranulation of NK cell subsets revealed a significant response increased by dinutuximab. This was irrespective of the KIR receptor–ligand constellation within the NK subsets, defined by the major KIR receptors CD158a, CD158b, and CD158e. Moreover, complement-dependent cytotoxicity (CDC) was shown to be an extremely potent effector-cell independent mechanism of tumor cell lysis, with a clear positive correlation to GD2 expression on the cancer cells as well as to the dinutuximab concentrations. The ex vivo testing of patient-derived effector cells and the sera collected during dinutuximab therapy demonstrated both high functionality of the newly established lymphoid immune compartment and provided confidence that the antibody dosing regimen was sufficient over the duration of the dinutuximab therapy (up to nine cycles in a 9-month period). During the course of the dinutuximab therapy, proinflammatory cytokines and markers (sIL2R, TNFa, IL6, and C reactive protein) were significantly elevated indicating a strong anti-GD2 immune response. No impact of FcGR polymorphism on event-free and overall survival was found. Collectively, this study has shown that in-patient functional immunomonitoring is feasible and valuable in contributing to the understanding of anti-cancer combinatorial treatments such as haplo SCT and antibody immunotherapy.

Published
2021

11. Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting

Author

Seitz, Christian M., primary, Mittelstaet, Joerg, additional, Atar, Daniel, additional, Hau, Jana, additional, Reiter, Selina, additional, Illi, Clara, additional, Kieble, Verena, additional, Engert, Fabian, additional, Drees, Britta, additional, Bender, Giulia, additional, Krahl, Ann-Christin, additional, Knopf, Philipp, additional, Schroeder, Sarah, additional, Paulsen, Nikolas, additional, Rokhvarguer, Alexander, additional, Scheuermann, Sophia, additional, Rapp, Elena, additional, Mast, Anna-Sophia, additional, Rabsteyn, Armin, additional, Schleicher, Sabine, additional, Grote, Stefan, additional, Schilbach, Karin, additional, Kneilling, Manfred, additional, Pichler, Bernd, additional, Lock, Dominik, additional, Kotter, Bettina, additional, Dapa, Sandra, additional, Miltenyi, Stefan, additional, Kaiser, Andrew, additional, Lang, Peter, additional, Handgretinger, Rupert, additional, and Schlegel, Patrick, additional

Published
2021
Full Text
View/download PDF

12. Novel Adapter CAR-T cell Technology for precisely controllable Multiplex Cancer Targeting

Author

Seitz, Christian, primary, Mittelstaet, Joerg, additional, Hau, Jana, additional, Reiter, Selina, additional, Illi, Clara, additional, Kieble, Verena, additional, Engert, Fabian, additional, Drees, Britta, additional, Bender, Giulia, additional, Atar, Daniel, additional, Krahl, Ann-Christin, additional, Knopf, Philipp, additional, Schroeder, Sarah, additional, Paulsen, Nikolas, additional, Rokhvarguer, Alexander, additional, Scheuermann, Sophia, additional, Rapp, Elena, additional, Mast, Anna-Sophia, additional, Rabsteyn, Armin, additional, Schleicher, Sabine, additional, Grote, Stefan, additional, Schilbach, Karin, additional, Kneilling, Manfred, additional, Pichler, Bernd, additional, Lock, Dominik, additional, Kotter, Bettina, additional, Dapa, Sandra, additional, Miltenyi, Stefan, additional, Kaiser, Andrew, additional, Lang, Peter, additional, Handgretinger, Rupert, additional, and Schlegel, Patrick, additional

Published
2020
Full Text
View/download PDF

14. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells

Author

Seitz, Christian M., primary, Schroeder, Sarah, additional, Knopf, Philipp, additional, Krahl, Ann-Christin, additional, Hau, Jana, additional, Schleicher, Sabine, additional, Martella, Manuela, additional, Quintanilla-Martinez, Leticia, additional, Kneilling, Manfred, additional, Pichler, Bernd, additional, Lang, Peter, additional, Atar, Daniel, additional, Schilbach, Karin, additional, Handgretinger, Rupert, additional, and Schlegel, Patrick, additional

Published
2019
Full Text
View/download PDF

15. Novel interface nitridation process for thin gate oxides

Author

Rahat, Ido, Shappir, Joseph, and Ben-Atar, Daniel

Subjects
Nitriding -- Research, Gates (Electronics) -- Research, Dielectrics -- Research, Oxides -- Research, Business, Electronics, Electronics and electrical industries
Abstract

Extremely thin gate dielectric films exhibit properties capable of controlling pure thermal oxides. Thermal nitridation of the silicon wafers in pure ammonia yield the thin films after high temperature oxide deposition. Perfect electrical characteristics are exhibited by the films when they are subjected to the Fowler-Nordheim tunneling stress. There is also a decrease in the charge trapping and interface state generation.

Published
1993

16. CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies.

Author

Ureña-Bailén, Guillermo, Lamsfus-Calle, Andrés, Daniel-Moreno, Alberto, Raju, Janani, Schlegel, Patrick, Seitz, Christian, Atar, Daniel, Antony, Justin S, Handgretinger, Rupert, and Mezger, Markus

Subjects
CELLULAR therapy, CHIMERIC antigen receptors, GENOME editing, GENE therapy, TECHNOLOGICAL innovations, CYTOTOXIC T cells
Abstract

Chimeric antigen receptor (CAR)-modified T cells have raised among other immunotherapies for cancer treatment, being implemented against B-cell malignancies. Despite the promising outcomes of this innovative technology, CAR-T cells are not exempt from limitations that must yet to be overcome in order to provide reliable and more efficient treatments against other types of cancer. The purpose of this review is to shed light on the field of CAR-T cell gene editing for therapy universalization and further enhancement of antitumor function. Several studies have proven that the disruption of certain key genes is essential to boost immunosuppressive resistance, prevention of fratricide, and clinical safety. Due to its unparalleled simplicity, feasibility to edit multiple gene targets simultaneously, and affordability, CRISPR/CRISPR-associated protein 9 system has been proposed in different clinical trials for such CAR-T cell improvement. The combination of such powerful technologies is expected to provide a new generation of CAR-T cell-based immunotherapies for clinical application. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

17. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.

Author

Seitz, Christian M., Schroeder, Sarah, Knopf, Philipp, Krahl, Ann-Christin, Hau, Jana, Schleicher, Sabine, Martella, Manuela, Quintanilla-Martinez, Leticia, Kneilling, Manfred, Pichler, Bernd, Lang, Peter, Atar, Daniel, Schilbach, Karin, Handgretinger, Rupert, and Schlegel, Patrick

Subjects
CHIMERIC antigen receptors, BREAST cancer, CANCER cells, TRIPLE-negative breast cancer, LYSIS, HORMONE receptor positive breast cancer
Abstract

Expression of the disialoganglioside GD2 has been identified as a marker antigen associated with a breast cancer stem-like cell (BCSC) phenotype. Here, we report on the evaluation of GD2 as a BCSC-specific target antigen for immunotherapy. GD2 expression was confirmed at variable degree in a set of breast cancer cell lines, predominantly in triple-negative breast cancer (TNBC). To target GD2, we have generated novel anti-GD2 chimeric antigen receptors (GD2-CAR), based on single-chain variable fragments (scFv) derived from the monoclonal antibody (mAb) ch14.18, also known as dinutuximab beta. Expressed on T cells, GD2-CARs mediated specific GD2-dependent T-cell activation and target cell lysis. In contrast to previously described GD2-CARs, no signs of exhaustion by tonic signaling were found. Importantly, application of GD2-CAR expressing T cells (GD2-CAR-T) in an orthotopic xenograft model of TNBC (MDA-MB-231) halted local tumor progression and completely prevented lung metastasis formation. In line with the BCSC model, GD2 expression was only found in a subpopulation (4-6%) of MDA-MB-231 cells before injection. Significant expansion of GD2-CAR-T in tumor-bearing mice as well as T-cell infiltrates in the primary tumor and the lungs were found, indicating site-specific activation of GD2-CAR-T. Our data strongly support previous findings of GD2 as a BCSC-associated antigen. GD2-targeted immunotherapies have been extensively studied in human. In conclusion, GD2-CAR-T should be considered a promising novel approach for GD2-positive breast cancer, especially to eliminate disseminated tumor cells and prevent metastasis formation. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

18. Rational Combinatorial Targeting By Adapter CAR T Cells (AdCAR-T) Prevents Antigen Escape in Acute Myeloid Leukemia (AML)

Author

Atar, Daniel, Ruoff, Lara, Mast, Anna-Sophia, Krost, Simon, Moustafa-Oglou, Moustafa, Scheuermann, Sophia, Kristmann, Beate, Feige, Maximilian, Canak, Aysegül, Wolsing, Katrin, Schilbach, Karin, Zekri, Latifa, Ebinger, Martin, Nixdorf, Daniel, Subklewe, Marion, Schulte, Johannes, Lengerke, Claudia, Werchau, Niels, Mittelstaet, Joerg, Lang, Peter, Handgretinger, Rupert, Schlegel, Patrick, and Seitz, Christian Martin

Abstract

Targeting AML by chimeric antigen receptor T cells (CAR-T) has been challenging due to promiscuous expression of AML-associated antigens on healthy hematopoietic stem and progenitor cells as well as a high degree of inter- and intratumoral heterogeneity. Consequently, we did not yet see the dramatic clinical successes as in B-phenotypic malignancies treated with CD19 or BCMA directed CAR-T.

Published
2023
Full Text
View/download PDF

19. Attracting 'olim' to the rest of Israel

Author

Atar, Daniel

Subjects
General interest, News, opinion and commentary
Abstract

JERUSALEM -- Nefesh B'Nefesh and Keren Kayemeth LeIsrael announced last week the launch of a new joint initiative, 'Go Beyond.' The two organizations have been working together successfully since 2012 [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results